All In Biotech

Drug Trial Radar · NCT06114628

Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB

A Seamless Phase 2B/C Platform Trial to Evaluate Multiple Regimens and Durations of Treatment in Pulmonary Tuberculosis

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 2,500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,500

Planned (sponsor's estimate)

Start

Jan 9, 2024

Primary completion

Feb 24, 2027

Study completion Aug 11, 2027

Sponsor

Lead sponsor
University College, LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Radboud University Medical Center; London School of Hygiene and Tropical Medicine; University of Oxford; Research Center Borstel; Lygature; TASK Applied Science; Università Vita-Salute San Raffaele; Helmholtz Zentrum Munchen; KNCV Tuberculosis Foundation; Critical Path Institute; European Lung Foundation; Instituto de Saude Publica da Universidade do Porto; University of Liverpool; Institut de Recherche pour le Developpement; University of Hamburg-Eppendorf; University of California, San Francisco; TB Alliance; Find; University of Milan; University of St Andrews; Uppsala University; European Respiratory Society; Tuberculosis Network European Trialsgroup; Janssen, LP; Otsuka Pharmaceutical Development & Commercialization, Inc.; German Center for Infection Research; LMU Klinikum; University of Cambridge; GlaxoSmithKline
First posted
Nov 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The UNITE4TB consortium is a group of universities and pharmaceutical companies funded by the European Union. This consortium are carrying out a trial to find better and faster ways to treat tuberculosis (TB). The standard treatment for TB takes 24 weeks and uses four drugs. The consortium want to find new treatments that are faster but just as safe and effective. In the trial, two new drugs will be used, BTZ-043 and GSK3036656, along with the drugs that are already used to treat TB in a variety of combinations (11 different combinations initially). These new drugs have worked well in tests with animals and have reduced the amount of TB bacteria in people's sputum/phlegm when used alone for two weeks. These new drugs will be used in combination with other TB drugs for a longer time (up to 16 weeks) in people with TB. The UNITE4TB consortium want to see if they work well and are safe. This trial will take place at sites across the world and will involve people with TB of the lungs that would usually respond well to the standard treatment. But the new treatments being tested might also work for people with drug resistant TB, that's harder to treat. The trial has two parts. In the first part, different combinations of drugs will be tried on up to 700 people for 16 weeks. These combinations will be compared to the standard 24-week treatment to see which ones work the best and are safe. In the second part, the best combinations from the first part will be taken to try to find out what the best length of time is to give the treatment for. These combinations will be tried on up to 1800 people giving them either 8, 10, 12, 14 or 16 weeks treatment. The investigators will follow these people for a total of 72 weeks to make sure the treatment is working. The UNITE4TB consortium hope that this trial will find new treatments that are fast, safe, and effective for both regular TB and resistant TB. If it works, it can then be tested again in a bigger trial to be sure.

Conditions

  • Pulmonary Tuberculosis

Interventions

  • GanfeboroleDrug

    Oral daily dosage of 20mg.

  • BTZ-043Drug

    Oral daily dosage of 1000mg.

  • Bedaquiline (B)Drug

    Oral daily dosage of 400mg for the first 2 weeks, thereafter 100mg daily until end of treatment.

  • Delamanid (D)Drug

    Oral daily dosage of 300mg.

  • Pretomanid (Pa)Drug

    Oral daily dosage of 200mg.

  • Moxifloxacin (M)Drug

    Oral daily dosage of 400mg.

  • Linezolid (L)Drug

    Oral daily dosage of 600mg for the first 8 weeks.

  • Pyrazinamide (Z)Drug

    Oral daily dosage of 1200mg-2000mg depending on weight.

  • Rifampicin (R)Drug

    Oral daily dosage of 450mg-750mg depending on weight.

  • Isoniazid (H)Drug

    Oral daily dosage of 225mg-375mg depending on weight.

  • Ethambutol (E)Drug

    Oral daily dosage of 825mg-1375mg depending on weight.

  • Delpazolid (DZD)Drug

    Oral daily dosage of 1200mg

  • Quabodepistat (Q)Drug

    Oral daily dosage of 30mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of change in log10(Time to Positivity of MGIT culture) (Phase 2B)Time frame: Over 0-12 weeks
  2. Favourable/Unfavourable outcome (Phase 2C)Time frame: at 48 weeks from randomisation

Locations

11 sites in 5 countries. Site status is shown where the registry gives one.

  • PMSI Institute of Pneumology "Chiril Draganiuc"

    Chisinau, Moldova · Active not recruiting

  • TASK Brooklyn

    Cape Town, South Africa · Recruiting

  • University of Cape Town Lung Institute

    Cape Town, South Africa · Recruiting

  • TASK Eden

    George, South Africa · Recruiting

  • NIMR Mbeya

    Mbeya, Tanzania · Recruiting

  • Kibong'oto Infectious Diseases Hospital

    Moshi, Tanzania · Recruiting

  • NIMR Mwanza

    Mwanza, Tanzania · Recruiting

  • Joint Clinical Research Centre

    Kampala, Uganda · Recruiting

  • Makerere University Lung Institute

    Kampala, Uganda · Recruiting

  • National Lung Hospital

    Hanoi, Vietnam · Active not recruiting

  • Pnth/Oucru

    Ho Chi Minh City, Vietnam · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.